Treatment with a class I histone deacetylase inhibitor (HDACi-109) reverses histone hypoacetylation, restores the abnormal FXN nucleosomal organization, and partially restores FXN transcript and frataxin protein in various pre-clinical FRDA models and in FRDA patients (Herman et al., 2006; Sandi et al., 2011; Soragni et al., 2014; Chutake et al., 2016). This evidence concerns the gene FXN and Friedreich ataxia.